WO2001083816A3 - Method for detecting tumors - Google Patents

Method for detecting tumors Download PDF

Info

Publication number
WO2001083816A3
WO2001083816A3 PCT/IB2001/000899 IB0100899W WO0183816A3 WO 2001083816 A3 WO2001083816 A3 WO 2001083816A3 IB 0100899 W IB0100899 W IB 0100899W WO 0183816 A3 WO0183816 A3 WO 0183816A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumors
component
detecting tumors
sample
tenascin
Prior art date
Application number
PCT/IB2001/000899
Other languages
French (fr)
Other versions
WO2001083816A2 (en
Inventor
Dario Neri
Francesca Viti
Original Assignee
Philogen Srl
Dario Neri
Francesca Viti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Srl, Dario Neri, Francesca Viti filed Critical Philogen Srl
Priority to AU58679/01A priority Critical patent/AU5867901A/en
Publication of WO2001083816A2 publication Critical patent/WO2001083816A2/en
Publication of WO2001083816A3 publication Critical patent/WO2001083816A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Detection of tumors, including latent tumors, by analysing the bodily fluid of an individual, in particular by determining the presence or absence of tumors in a body fluid sample of mRNA encoding an extracellular matrix component in said sample, which component is specifically found in tumors. The component may be fibronectin ED-A, ED-B, or large isoform of tenascin C.
PCT/IB2001/000899 2000-05-04 2001-05-03 Method for detecting tumors WO2001083816A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58679/01A AU5867901A (en) 2000-05-04 2001-05-03 Method for detecting tumors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20186400P 2000-05-04 2000-05-04
US60/201,864 2000-05-04

Publications (2)

Publication Number Publication Date
WO2001083816A2 WO2001083816A2 (en) 2001-11-08
WO2001083816A3 true WO2001083816A3 (en) 2003-03-13

Family

ID=22747609

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000899 WO2001083816A2 (en) 2000-05-04 2001-05-03 Method for detecting tumors

Country Status (2)

Country Link
AU (1) AU5867901A (en)
WO (1) WO2001083816A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9513298B2 (en) 2004-07-30 2016-12-06 Hologic, Inc. Methods for detecting oncofetal fibronectin

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868618C (en) 2002-10-16 2017-05-23 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
EP2142567B1 (en) 2007-04-02 2013-01-16 Philogen S.p.A. The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
NO2209805T3 (en) 2007-10-30 2018-02-03
EP2379116B1 (en) 2009-01-07 2015-08-26 Philogen S.p.A. Antigens associated with endometriosis
EP2947096B1 (en) 2009-08-05 2018-11-28 Philogen S.p.A. Targeting of bone marrow neovasculature
WO2014055073A1 (en) 2012-10-03 2014-04-10 Philogen S.P.A. Antigens associated with inflammatory bowel disease
CN108291915B (en) * 2015-11-16 2021-01-05 合肥立方制药股份有限公司 Application of ED-B protein in diagnosis of tissue hyperplasia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015602A1 (en) * 1991-02-28 1992-09-17 Dana-Farber Cancer Institute, Inc. Cancer diagnosis and therapy
US5981218A (en) * 1995-08-09 1999-11-09 Bristol-Myers Squibb Company Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis and encoded polypeptides
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015602A1 (en) * 1991-02-28 1992-09-17 Dana-Farber Cancer Institute, Inc. Cancer diagnosis and therapy
US5981218A (en) * 1995-08-09 1999-11-09 Bristol-Myers Squibb Company Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis and encoded polypeptides
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALBRECHT MARTIN ET AL: "Fibronectin in human prostatic cells in vivo and in vitro: Expression, distribution, and pathological significance.", HISTOCHEMISTRY AND CELL BIOLOGY, vol. 112, no. 1, July 1999 (1999-07-01), pages 51 - 61, XP002218305, ISSN: 0948-6143 *
MICHELL A J ET AL: "HUMAN TENASCIN-C: IDENTIFICATION OF A NOVEL TYPE III REPEAT IN ORAL CANCER AND OF NOVEL SPLICE VARIANTS IN NORMAL, MALIGNANT AND REACTIVE ORAL MUCOSAE", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 72, 1997, pages 236 - 240, XP000937664, ISSN: 0020-7136 *
NICOLO G ET AL: "EXPRESSION OF TENASCIN AND OF THE ED-B CONTAINING ONCOFETAL FIBRONECTIN ISOFORM IN HUMAN CANCER", CELL DIFFERENTIATION AND DEVELOPMENT, vol. 32, no. 3, 1990, pages 401 - 408, XP008009720, ISSN: 0922-3371 *
OYAMA FUMITAKA ET AL: "Coordinate oncodevelopmental modulation of alternative splicing of fibronectin pre-messenger RNA at ED-A, ED-B, and CS1 regions in human liver tumors.", CANCER RESEARCH, vol. 53, no. 9, 1993, pages 2005 - 2011, XP002218306, ISSN: 0008-5472 *
VOLLMER G ET AL: "EXPRESSION OF TENASCIN-C BY HUMAN ENDOMETRIAL ADENOCARCINOMA AND STROMA CELLS: HETEROGENEITY OF SPLICE VARIANTS AND INDUCTION BY TGF-BETA", BIOCHEMISTRY AND CELL BIOLOGY. BIOCHIMIE ET BIOLOGIE CELLULAIRE, XX, XX, vol. 75, 1997, pages 759 - 769, XP000937670, ISSN: 0829-8211 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9513298B2 (en) 2004-07-30 2016-12-06 Hologic, Inc. Methods for detecting oncofetal fibronectin

Also Published As

Publication number Publication date
WO2001083816A2 (en) 2001-11-08
AU5867901A (en) 2001-11-12

Similar Documents

Publication Publication Date Title
EP1700912A4 (en) Method of detecting target molecule by using aptamer
WO2004063753A3 (en) A serum marker for measuring liver fibrosis
WO2005041893A3 (en) Detection of acute myocardial infarction biomarkers
WO2004099432A3 (en) Identification of biomarkers for detecting pancreatic cancer
WO2008041953A3 (en) Dengue diagnosis and treatment
WO2007064567A3 (en) Apparatus and method for measuring real-time corrosion
SG169395A1 (en) Detection of cancer by elevated levels of bcl-2
WO2002097415A3 (en) Analytical instruments, biosensors and methods
WO2005113817A3 (en) Aptamer-nanoparticle conjugates and method of use for target analyte detection
WO2004055519A3 (en) Specific markers for pancreatic cancer
WO2006020579A3 (en) Method for rapid identification of microorganisms
AU2003238869A8 (en) Hybrid microcantilever sensors
EP1381864A4 (en) Detection of candida
EP1383914A4 (en) Improved method for detection of atp
GB0603665D0 (en) Protease detection
IL181131A0 (en) USE OF C3a AND DERIVATIVES THEREOF AS A BIOMARKER FOR COLORECTAL ADEMONA AND/OR CARCINOMA; DIAGNOSIS METHOD AND TEST SYSTEM USING THE SAME
WO2008060651A8 (en) Sparc and methods of use thereof
WO2006002243A3 (en) Methods of oligosaccharide profiling for the detection of cancer
WO2001055719A3 (en) Diagnostic kit for detecting creatine levels
WO2001083816A3 (en) Method for detecting tumors
MX2021016095A (en) NEW DIAGNOSTIC MARKER FOR PANCREATIC CANCER.
WO2004057336A3 (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
WO2003057014A3 (en) Biomarkers for detecting ovarian cancer
WO2003091695A3 (en) Identification of biomarkers for detecting prostate cancer
WO2003076896A3 (en) Use of biomarkers to detect breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP